What should tesamorelin peptide counterion acetate vs TFA documentation list on a CoA?
A complete certificate of analysis for a tesamorelin research lot should treat the counterion as a named analyte rather than as a decorative suffix in the material name. Published chemical literature describes tesamorelin as a synthetic growth hormone-releasing factor analogue, which is an identity statement about the polypeptide; it does not substitute for a measured anion assay on a given batch (PMID:17086939; PMID:19243281). The CoA identity block should therefore keep sequence-level confirmation and salt-form confirmation in separate fields.
Minimum fields include: declared salt form (acetate, trifluoroacetate, mixed counterion, or free base with residual acid); counterion content as percent by weight, with method and calibration basis; water content, typically by Karl Fischer coulometry; chromatographic purity as area percent under a fully identified reversed-phase method; mass-spectrometric identity against the theoretical mass of the modified chain; net peptide content with the arithmetic shown; and the lot number that matches the vial. Where a laboratory reports 'tesamorelin acetate' without an acetate number, the phrase is nomenclature, not data. Where a laboratory reports 'TFA: conforms' without a numeric limit, the field is a qualitative flag and cannot support a mass-balance calculation.
Acetate and trifluoroacetate can coexist. Lots purified in trifluoroacetic acid ion-pair systems may retain TFA after an intended exchange into acetate. Documentation should state whether the reported anion is the intended counterion, a residual process-related ion, or both, and should give units that a second laboratory can reproduce: percent weight/weight, or moles of anion per mole of peptide. Mixed-salt lots should not be assigned a single theoretical stoichiometry as if it had been confirmed.
Attachments should travel with the CoA: the ion-chromatography trace or fluorine-19 nuclear magnetic resonance spectrum used for TFA, the reversed-phase chromatogram, the mass spectrum, and a method identifier covering column chemistry, detection, and system-suitability outcome.
How do acetate and trifluoroacetate arise on synthetic tesamorelin lots?
Solid-phase peptide synthesis of a long modified chain such as tesamorelin typically ends with acidolytic cleavage and deprotection in a trifluoroacetic acid cocktail. The crude peptide therefore first appears as a trifluoroacetate-associated solid or solution. Subsequent reversed-phase purification commonly uses trifluoroacetic acid as an ion-pair reagent to sharpen peak shape and to control retention of a cationic peptide. Under those conditions TFA is an intentional mobile-phase additive that remains available to bind the peptide during fraction collection and lyophilisation. A lot that never undergoes a documented salt exchange is therefore expected to carry TFA as the dominant counterion unless an orthogonal measurement shows otherwise.
Acetate appears when a laboratory exchanges the anion by a second chromatographic step, a volatile-buffer lyophilisation, or a resin-based ion exchange into acetic acid or ammonium acetate systems. The exchange is a process, not a label claim. Incomplete exchange leaves a mixed-counterion solid in which acetate may dominate by mole fraction while TFA remains at a residual level that still affects mass balance and, in some reversed-phase methods, peak shape.
TFA reported after a TFA-based purification without exchange is consistent with process chemistry. TFA reported after a claimed acetate exchange is a residual-ion specification and should be numerically low relative to acetate. Acetate reported without a TFA result cannot exclude residual trifluoroacetate. Because tesamorelin is a defined synthetic analogue in the literature, assuming a single clean salt form is a documentation gap unless both anions have been looked for (PMID:21283099; PMID:22298602).
Research purchasers in Australia should ask whether the supplier's purification train is TFA-based, acetate-based or mixed, and whether the CoA method can see both anions. A narrative that says 'acetate salt' because acetic acid was present in a final lyophilisation buffer is weaker than a chromatogram that integrates acetate and shows TFA below a stated reporting threshold.
Which methods quantify acetate versus TFA on tesamorelin research solids?
Ion chromatography with suppressed conductivity detection is the workhorse for small organic anions on peptide solids. Acetate and trifluoroacetate are well resolved on modern anion-exchange columns, and both can be calibrated with independently prepared standards. Sample preparation must dissolve the tesamorelin solid completely and must not introduce acetate from glassware residues or from acetic acid in the diluent if acetate is the analyte. A reagent blank and a method blank belong in the sequence. Results are typically reported as percent weight/weight relative to the as-is solid; converting to moles of anion per mole of peptide requires an independent peptide-content value and the molecular mass of the free peptide, not the salt.
Fluorine-19 nuclear magnetic resonance spectroscopy is an orthogonal option for TFA because the trifluoromethyl resonance is distinctive. Quantitative 19F work needs an internal standard with a known fluorine count, adequate relaxation delays, and a stated limit of quantification. It does not measure acetate, so it cannot close mass balance on an acetate-declared lot by itself. Reversed-phase HPLC with ultraviolet detection is a poor primary assay for these counterions: acetate is weakly retained and poorly chromophoric at conventional peptide wavelengths, and TFA is usually invisible in the peptide ultraviolet trace even when it is abundant in the solid. Using the peptide purity chromatogram as a surrogate for salt-form identity is a category error.
Mass spectrometry confirms the peptide chain, including the N-terminal hexenoyl modification that distinguishes tesamorelin as a defined analogue in published identity discussions, but electrospray spectra do not quantify the counterion that was present in the lyophilised cake (PMID:19243281; PMID:21283099). TFA adducts in the spectrum are at most a qualitative hint. Laboratories that report only HPLC area percent and a matching mass have not documented the salt form.
Acceptance criteria should be measurable. Research quality systems commonly require numeric acetate and TFA limits, a mass-balance sum, and ion-chromatography resolution between the two anions.
How is net peptide content reconciled with counterion, water and solvents?
HPLC area percent describes the distribution of ultraviolet-active related substances in a chromatogram. The as-is solid is a mixture of peptide, counterion, water and often residual process solvents. Net peptide content is the fraction of that solid that is the polypeptide after non-peptide mass has been accounted for. Without a counterion number, a water number and a stated calculation, chromatographic purity and a labelled vial mass cannot be converted into peptide amount with a defensible uncertainty.
One common research-laboratory approach derives an as-is peptide fraction from nitrogen content, amino-acid analysis or a calibrated chromatographic assay, then cross-checks against 100 percent minus water minus counterion minus residual solvents, with any unaccounted mass shown explicitly. Another approach multiplies the weighed solid by one minus water minus TFA minus acetate minus other volatiles, then by chromatographic purity, which is valid only if purity and the subtracted terms do not double-count the same impurities. The CoA should name which approach was used.
Acetate and TFA are not interchangeable in that arithmetic. Trifluoroacetate has a higher molecular mass than acetate, so the same molar salt stoichiometry removes a larger weight fraction from the solid when TFA is the counterion. A lot labelled as acetate but still carrying several percent TFA will be mis-corrected if only a theoretical acetate stoichiometry is applied. This is why tesamorelin peptide counterion acetate vs TFA documentation is a quantitative requirement, not a naming preference. The molecular mass used for mole-fraction calculations must be the free peptide mass consistent with the published analogue structure, not an arbitrary salt mass taken from a catalogue line (PMID:17086939).
Residual solvents deserve their own line when purification used large volumes of acetonitrile or methanol. Headspace gas chromatography is the usual method; 'residual solvents: not tested' leaves a hole in the mass balance. If unaccounted mass after peptide, counterion, water and solvents is large, the documentation should say so rather than forcing the numbers to 100 percent.
What lot-traceability pack should Australian laboratories request with tesamorelin?
Supplier evaluation for tesamorelin research material in Australia is a documentation exercise. The peptide is identified in the literature as a synthetic growth hormone-releasing factor analogue, so a purchaser is entitled to ask for identity data that match that chemical definition and for salt-form data that those papers do not themselves provide (PMID:22298602; PMID:21668043). A practical pack contains a certificate of analysis tied to a unique lot number, the HPLC chromatogram with integration report, a mass spectrum supporting the intact chain, a counterion report that distinguishes acetate from TFA, water content, net peptide content with the calculation, and a statement of the testing laboratory. Where several vials share a lot, the pack should say so, so that multi-vial orders are not mistaken for independently tested sub-lots.
Local Australian stock and tracked dispatch preserve chain of custody from the released lot to the receiving laboratory. The receiving record should capture the lot number, the number of vials and the CoA identifier. Batch documentation should be filed so that an unexpected HPLC profile, a mismatched mass or a counterion result that does not match the label can be traced to a specific release package rather than to an undated catalogue PDF.
Comparison of salt form is only meaningful when the methods are visible. An acetate-labelled lot with ion-chromatography data can be compared with a TFA-labelled lot with 19F data; an acetate-labelled lot with no anion assay cannot. Laboratories should confirm that related-substance methods name column, gradient and detection, because ion-pair TFA methods and acetate-buffered methods do not always reveal the same impurity set.
This pack does not replace the receiving laboratory's own orthogonal check when the study requires it. It is the minimum that allows a materials section to name the salt form honestly. Research supply should be evaluated on whether the counterion page of the CoA is quantitative.
Order Tesamorelin with documentation
If this guide helped you evaluate Tesamorelin for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Tesamorelin card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Does a tesamorelin CoA need both acetate and TFA results?
If the lot is declared as an acetate salt, the CoA should quantify acetate and should either quantify TFA or show it below a stated limit of quantification. TFA-declared lots should quantify TFA and should not assume acetate is absent without a measurement. Mixed-counterion lots should report both anions with units that support mass-balance arithmetic.
Why is HPLC area percent not a counterion assay?
Area percent records ultraviolet-active peptide-related substances. Acetate is poorly chromophoric at peptide wavelengths and TFA is typically invisible in that trace. Salt-form identity requires ion chromatography, quantitative 19F NMR for TFA, or another anion-specific method, plus a calculation that converts those results into net peptide content.
What files should Australian laboratories keep with a tesamorelin lot?
Keep the lot-linked CoA, HPLC integration report, mass spectrum, counterion chromatogram or 19F spectrum, water result, net-content calculation, and the tracked-dispatch record that ties vials to that lot. File multi-vial orders so shared lots are visible. Local Australian stock records should match the same lot number as the analytical pack.
How does TFA versus acetate change net peptide content?
Trifluoroacetate is heavier than acetate, so the same molar stoichiometry accounts for a larger non-peptide weight fraction. Applying the wrong theoretical salt correction biases peptide amount. Documentation should use measured anion content, measured water, and the free-peptide molecular mass rather than a catalogue salt mass.
Is tesamorelin identity the same as salt-form identity?
No. Literature identity as a synthetic growth hormone-releasing factor analogue addresses the polypeptide, including the hexenoyl modification discussed in chemical reviews. Counterion identity is a separate measurement on the isolated solid and must appear as its own CoA field. Both belong in the lot file.
References
- PMID:17086939 — Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor — Curr Opin Investig Drugs — 2006
- PMID:19243281 — Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs — 2009
- PMID:21283099 — Tesamorelin — Nat Rev Drug Discov — 2011
- PMID:22298602 — Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Ann Pharmacother — 2012
- PMID:21668043 — Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy — Drugs — 2011
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
